Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04450069
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:15.766098+00:00
Published At
2024-08-20T00:00:00+00:00
Record Updated At
2024-08-20
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Relapsed/Refractory B-cell Lymphomas", "Diffuse Large B Cell Lymphoma (DLBCL)", "Follicular Lymphoma (FL)", "Chronic Lymphocytic Leukemia (CLL)", "Marginal Zone Lymphoma (MZL)", "Mantle Cell Lymphoma", "Small Lymphocytic Lymphoma (SLL)", "Primary Mediastinal Large B Cell Lymphoma", "Transformed Follicular Lymphoma", "Waldenstrom Macroglobulinemia", "Lymphoplasmacytic Lymphoma", "Burkitt Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-08-20"
protocolSection.identificationModule.nctId
"NCT04450069"
protocolSection.identificationModule.officialTitle
"A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Relapsed/Refractory B-cell Lymphomas (protocolSection.conditionsModule.conditions)
  • Diffuse Large B Cell Lymphoma (DLBCL) (protocolSection.conditionsModule.conditions)
  • Follicular Lymphoma (FL) (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia (CLL) (protocolSection.conditionsModule.conditions)
  • Marginal Zone Lymphoma (MZL) (protocolSection.conditionsModule.conditions)
  • Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Small Lymphocytic Lymphoma (SLL) (protocolSection.conditionsModule.conditions)
  • Primary Mediastinal Large B Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Transformed Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Waldenstrom Macroglobulinemia (protocolSection.conditionsModule.conditions)
  • Lymphoplasmacytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Burkitt Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.